Supernus Pharmaceuticals, Inc.
SUPN · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $1,992 | $1,578 | $1,914 | $1,548 |
| - Cash | $69 | $75 | $93 | $203 |
| + Debt | $34 | $42 | $438 | $421 |
| Enterprise Value | $1,957 | $1,545 | $2,259 | $1,765 |
| Revenue | $662 | $608 | $667 | $580 |
| % Growth | 8.9% | -8.9% | 15.1% | – |
| Gross Profit | $584 | $524 | $580 | $505 |
| % Margin | 88.2% | 86.2% | 86.9% | 87.1% |
| EBITDA | $178 | $90 | $153 | $129 |
| % Margin | 26.9% | 14.8% | 23% | 22.3% |
| Net Income | $74 | $1 | $61 | $53 |
| % Margin | 11.2% | 0.2% | 9.1% | 9.2% |
| EPS Diluted | 1.32 | 0.024 | 1.04 | 0.98 |
| % Growth | 5,469.6% | -97.7% | 6.1% | – |
| Operating Cash Flow | $172 | $111 | $117 | $127 |
| Capital Expenditures | -$1 | -$1 | -$0 | -$2 |
| Free Cash Flow | $171 | $111 | $116 | $125 |